Drugs / MitoCell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05094011 | Mar 2026 → Sep 2027 expected | Parkinson disease | Taiwan Mitochondrion Applied Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MitoCell | “MitoCell is an autologous stem cell product that cultures with the company's unique patented medium.” NCT05094011 ↗ |
| Modality | Cell therapy | “autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell)” NCT05094011 ↗ |
| Route | Other | “Stereotactic intrastriatal implantation” NCT05094011 ↗ |